Tran T, Assayag D, Ernst P, et al. - Whether proton pump inhibitors (PPIs) use is related to a reduction in all-cause death, respiratory-related mortality, and respiratory-related hospitalization among patients with idiopathic pulmonary fibrosis (IPF), was investigated in this study. A cohort comprising patients diagnosed with IPF between 2003 and 2016 was selected using the UK Clinical Practice Research Datalink. Experts used prevalent new-user cohort design to match patients starting PPIs with non-users applying time-conditional propensity scores, with follow-up until death or end of observation. In this large study with IPF patients within a real world setting of clinical practice and designed to avert biases impacting previous investigations, it was evident that PPI use was not related to lower death or hospitalization incidence. Experts inferred that benefit of PPIs in treating IPF may not be as much as suggested by some studies and conditionally recommended in treatment guidelines.